Volume 62, Issue 5, Pages (November 2012)

Slides:

Advertisements

Similar presentations

European Urology Focus

Advertisements

Volume 57, Issue 3, Pages (March 2010)

Early Detection of Prostate Cancer in 2007

Volume 56, Issue 5, Pages (November 2009)

Impact of LUTS Using Bother Index in DAN-PSS-1 Questionnaire

Volume 55, Issue 1, Pages 1-8 (January 2009)

Volume 72, Issue 1, Pages (July 2017)

Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit Pim J. van Leeuwen, David Connolly, Anna.

Volume 164, Issue 6, Pages (December 2000)

Volume 41, Issue 6, Pages (June 2002)

Volume 70, Issue 3, Pages (September 2016)

Volume 45, Issue 5, Pages (May 2004)

Volume 54, Issue 2, Pages (August 2008)

Volume 68, Issue 6, Pages (December 2015)

Volume 57, Issue 1, Pages (January 2010)

Volume 50, Issue 1, Pages (July 2006)

Volume 52, Issue 1, Pages (July 2007)

Volume 51, Issue 2, Pages (February 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

European Urology Focus

Testosterone Therapy in Men With Prostate Cancer

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 61, Issue 6, Pages (June 2012)

Volume 64, Issue 6, Pages (December 2013)

Volume 71, Issue 1, Pages (January 2017)

Volume 60, Issue 1, Pages (July 2011)

Volume 61, Issue 5, Pages (May 2012)

Volume 68, Issue 5, Pages (November 2015)

Volume 67, Issue 4, Pages (April 2015)

Volume 61, Issue 2, Pages (February 2012)

Prostate Cancer Epidemic in Sight?

Volume 61, Issue 3, Pages (March 2012)

Volume 63, Issue 4, Pages (April 2013)

Volume 68, Issue 5, Pages (November 2015)

Volume 54, Issue 4, Pages (October 2008)

Prostate Cancer Detection: A View of the Future

Volume 54, Issue 5, Pages (November 2008)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 69, Issue 3, Pages (March 2016)

Volume 66, Issue 3, Pages (September 2014)

Volume 66, Issue 6, Pages (December 2014)

Prostate Cancer Epidemic in Sight?

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Leonard S. Marks, Jiaoti Huang European Urology

Volume 63, Issue 3, Pages (March 2013)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 48, Issue 6, Pages (December 2005)

Volume 64, Issue 4, Pages (October 2013)

Volume 50, Issue 5, Pages (November 2006)

Volume 58, Issue 3, Pages (September 2010)

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 59, Issue 4, Pages (April 2011)

Volume 72, Issue 1, Pages (July 2017)

European Urology is “Your” Journal

Volume 65, Issue 6, Pages (June 2014)

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 52, Issue 6, Pages (December 2007)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 51, Issue 2, Pages (February 2007)

Volume 54, Issue 3, Pages (September 2008)

Does PSA Testing Influence the Natural History of Prostate Cancer?

Volume 52, Issue 5, Pages (November 2007)

Volume 76, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 62, Issue 5, Pages 745-752 (November 2012) Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Fritz H. Schröder, Jonas Hugosson, Sigrid Carlsson, Teuvo Tammela, Liisa Määttänen, Anssi Auvinen, Maciej Kwiatkowski, Franz Recker, Monique J. Roobol European Urology Volume 62, Issue 5, Pages 745-752 (November 2012) DOI: 10.1016/j.eururo.2012.05.068 Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 1 Flow diagram of the study. ERSPC=European Randomized Study of Screening for Prostate Cancer; PCa=prostate cancer. *Comprising data of four of the eight ERSPC centers: The Netherlands, Sweden, Finland (Tampere), and Switzerland. $ Percentage of men with M+ PCa that died. European Urology 2012 62, 745-752DOI: (10.1016/j.eururo.2012.05.068) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 2 Nelson-Aalen cumulative hazard estimates of M+ prostate cancer (a) overall, (b) at time of diagnosis, and (c) during follow-up. PCa=prostate cancer. European Urology 2012 62, 745-752DOI: (10.1016/j.eururo.2012.05.068) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 3 Rate per 10 000 person-years of M+ at diagnosis per study arm and by years after randomization. European Urology 2012 62, 745-752DOI: (10.1016/j.eururo.2012.05.068) Copyright © 2012 European Association of Urology Terms and Conditions